Sponsor: The Longevity Show
Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem, from breakthrough neurological therapeutics and pet longevity innovations to advances in neuroplasticity, wearable tech, and early-stage cardiovascular interventions.

• Vector Y’s ALS drug, VTX002, received Fast Track designation, targeting the TDP43 protein and marking a potential shift from symptom management to disease modification in ALS.
• Loyal’s senior dog longevity drug, LOY002, clears FDA safety hurdles, aiming to extend lifespan in large mammals while providing insights for human longevity applications.
• Cumulus introduces a scalable neuroplasticity measurement platform with wireless dry EEG sensors, allowing researchers to monitor brain adaptation and recovery in clinical settings efficiently.
• Significant investment activity continues in longevity-focused startups, including multi-million-dollar raises for cardiovascular disease prevention, extracellular matrix-targeted therapies, and regenerative biologics.

__________________

News & References:

• Vector Y wins FDA Fast Track for ALS therapy → https://longevity.technology/news/vectory-wins-fda-fast-track-for-als-therapy/
• FDA clears safety step for Loyal’s senior dog longevity drug → https://longevity.technology/news/fda-clears-safety-step-for-loyals-senior-dog-longevity-drug/
• Cumulus proves brain plasticity can be measured at scale → https://longevity.technology/news/cumulus-proves-brain-plasticity-can-be-measured-at-scale/
• Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery → https://longevity.technology/news/nvidia-and-eli-lilly-bet-1-billion-on-ai-powered-drug-discovery/
• 50M boost secured for BioBeat’s wearable blood pressure tech → https://longevity.technology/news/50m-boost-secured-for-biobeats-wearable-blood-pressure-tech/
• Engitix raises $25M to target tissue aging at its source → https://longevity.technology/news/engitix-raises-25m-to-target-tissue-aging-at-its-source/
• Corsera lands $80M to predict and prevent cardiovascular disease → https://longevity.technology/news/corsera-lands-80m-to-predict-and-prevent-cardiovascular-disease/
• Proxima lands $80M to make protein interactions programmable → https://longevity.technology/news/proxima-lands-80m-to-make-protein-interactions-programmable/

__________________

Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn

Guest: Lucas di Grassi

Website: https://digrassi.com/

Instagram: https://www.instagram.com/lucasdigrassi/

Sponsor: The Longevity Show

Website: https://longevityshow.com/

The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________________

What can professional racing teach us about health, longevity, and peak human performance?

Phil Newman and Dr. Nina Patrick sit down with Formula E and endurance racing champion Lucas di Grassi to explore how elite athletes optimize metabolism, nutrition, hydration, and supplementation to maintain health under extreme stress. Lucas shares his personal strategies, from microbiome-focused supplements and metabolic flexibility to controlling stress and tracking biological age.

Beyond personal optimization, Lucas discusses emerging technologies that could revolutionize human healthspan, including AI-driven digital twins, protein design with AlphaFold 2, and continuous biometric monitoring. He also shares his insights on how lessons from motorsport telemetry, environmental awareness, and data-driven decision-making can translate to everyday life and longevity.

This conversation combines the science of performance with practical insights for anyone seeking to improve healthspan, optimize lifestyle, and leverage technology to extend both lifespan and quality of life. Subscribe for weekly episodes on longevity science, health optimization, and the innovations shaping our future.

Key Topics:

• Lessons from professional racing for metabolism, nutrition, and hydration
• Stress management and biological age tracking
• AI-driven digital twins and protein design with AlphaFold 2
• Continuous biometric monitoring and data-driven health insights
• Translating elite performance strategies to everyday longevity

If you care about living longer and healthier while optimizing your performance and lifestyle, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.

__________

Connect with our hosts:

Phil Newman: https://qrco.de/bgXpNY

Dr. Nina Patrick: https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem from validated lifestyle science and AI-driven drug discovery to breakthrough clinical trials, CES health tech, and the future of longevity investing.

• A new study in the International Journal of Epidemiology confirms that Blue Zone populations still enjoy statistically significant longevity advantages, highlighting the role of community, movement, and diet in healthy aging.
• Insilico Medicine made headlines with its Hong Kong IPO, raising $293M and signaling strong investor confidence in AI-driven longevity biotech. The company also secured an $888M oncology collaboration with Servier, marking a major step for AI-powered drug discovery.
• At CES, Withings unveiled its at-home Longevity Station, a device that measures 60 biomarkers in just 90 seconds. It tracks cardiovascular function, vascular health, cellular composition, and early cardiometabolic risk, bringing advanced health monitoring into the home.
• Retro Biosciences dosed the first patient in a phase one trial of its autophagy-targeting drug, RTR242, a key milestone for clinical-stage longevity therapeutics.
• Human clinical evidence from El Nutra’s ProLon fasting-mimicking diet demonstrates measurable activation of autophagy, supporting cellular renewal, improved insulin sensitivity, and metabolic health.

----------

News & References:

• Insilico debuts on HK stock exchange, locking in more than $290M → https://longevity.technology/news/insilico-debuts-on-hk-stock-exchange-locking-in-more-than-290m/
• Insilico Medicine and Servier agree up to US$888M oncology collaboration → https://longevity.technology/news/insilico-medicine-and-servier-agree-up-to-us888-m-oncology-drug-discovery-collaboration/
• Retro Bio commences first-in-human trial for RIP242 → https://longevity.technology/news/retro-bio-commences-first-in-human-trial/
• Why long-bio is poised for a breakout at JPM 2026 → https://longevity.technology/news/why-longbio-is-poised-for-a-breakout-at-jpm-2026/
• Withings launches at-home Longevity Station at CES → https://longevity.technology/news/withings-launches-at-home-longevity-station-at-ces/
• First human trial links fasting-mimicking diet to cellular renewal → https://longevity.technology/news/first-human-trial-links-fasting-mimicking-diet-to-cellular-renewal/
• New study reaffirms Blue Zones longevity claims → https://longevity.technology/news/new-study-reaffirms-blue-zones-longevity-claims/

----------

Connect with our hosts:

Phil Newman: https://qrco.de/bgXpNY

Dr. Nina Patrick: https://qrco.de/bgXpKn

GLP-1 drugs have exploded into the mainstream, but are they truly longevity medicines, or simply powerful tools for treating obesity and metabolic disease?

In the first episode Longevity.Technology UNLOCKED, hosts Phil Newman and Dr. Nina Patrick sit down with two of the world’s leading authorities to unpack one of the most important health debates of our time: Should we all be taking GLP-1 agonists?

Joining the conversation are Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, and Professor Jens Juul Holst, the scientist who first discovered the GLP-1 hormone. Together, they explore the science, hype, risks, and real-world implications of drugs like Ozempic, Wegovy, and tirzepatide going far beyond weight loss headlines.

From insulin resistance and inflammation to cardiovascular protection, brain health, and the future of preventive medicine, this wide-ranging discussion examines whether GLP-1s could redefine how we think about aging itself. The episode also tackles difficult questions around microdosing, off-label use, muscle loss, access, regulation, and the ethics of medicating lifestyle versus disease.

Key Topics:

• What GLP-1 agonists actually do in the body
• Obesity, metabolic syndrome, and lifespan
• Weight-independent longevity effects
• Inflammation, cardiovascular and renal protection
• Brain health and Alzheimer’s disease
• Microdosing, personalization, and patient-led experimentation
• Risks, side effects, and media exaggeration
• Are GLP-1s the first true preventive longevity drugs?

If you care about living longer and healthier and understanding the trade-offs along the way, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.

----------

Connect with our hosts:

Phil Newman: https://qrco.de/bgXpNY

Dr. Nina Patrick: https://qrco.de/bgXpKn

Longevity.Technology UNLOCKED is here!Phil Newman and Dr. Nina Patrick are launching a brand-new series exploring the ideas, science, and stories shaping how we live longer, healthier lives.First episode drops January 5th: GLP-1s – Should We All Be Taking Them? with Dr. Jens Juul Holst and Dr. Eric Verdin. Expect real science, clear answers, and practical takeaways you can actually use.Why subscribe now?

• Be the first to hear every episode

• Get insights from leading experts before they hit the headlines
• Learn actionable tips to optimize your healthspan

Join a curious, longevity-minded community#LongevityUnlocked #LongevityPodcast #FutureOfHealth #GLP1 #LongevityTechnology